Video Shorts

1:33

The Efficacy and Safety of Arlo-Cel for R/R Myeloma

8 months ago

Omar Nadeem, MD

1:00

All Eyes on DESTINY-Breast11 Readout for HER2+ Breast Cancer at ESMO 2025

8 months ago

Paolo Tarantino, MD

0:53

Don't Ignore the Signs: Why Increased Awareness of Early Endometrial Cancer Symptoms Is Critical

8 months ago

Dana Chase, MD

0:45

Is Early Mortality Associated With Real-World Bispecific Antibody Use in R/R Multiple Myeloma?

8 months ago

Carlyn Rose Tan, MD

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, Rutgers Cancer Institute

0:37

Unpacking Advances in the Surgical Management of Brain Cancer

8 months ago

Jonathan H. Sherman, MD, FAANS, FCNS, FACS

Ryan M. Kahn, MD, MHS, FACOG, of Baptist Health Miami Cancer Institute

1:01

Ongoing Challenges With Surgery in Ovarian Cancer

8 months ago

Ryan M. Khan, MD, MHS, FACOG

Michelle Monje, MD, PhD, of Stanford University

0:44

Using CAR T-Cell Therapy in Diffuse Midline Gliomas

8 months ago

Michelle Monje, MD, PhD

0:34

The Role of Minimally Invasive Surgery in Uterine Cancer

8 months ago

John Paul Diaz, MD

1:26

Real-World Outcomes of Patients With Newly Diagnosed Multiple Myeloma Treated with Front-Line DRd

8 months ago

Ricardo D. Parrondo, MD

1:24

Landmark Trials in Advanced Ovarian Cancer

9 months ago

Maurie Markman, MD

2:17

2025 IMS Annual Meeting: Experts Recap Latest Advances in Multiple Myeloma

9 months ago

Ashling Wahner

Ken Culver, MD, and D. Ross Camidge, MD, PhD

2:29

Managing Strategic and Patient Expectations in R&D

9 months ago

Ross Camidge, MD, PhD(+1 more)

1:58

Are Health Economists Promotional?

9 months ago

Ross Camidge, MD, PhD(+1 more)

Brandon Blue, MD, and D. Ross Camidge, MD, PhD

2:38

How I Became a Healer

9 months ago

Ross Camidge, MD, PhD(+1 more)

Heather McArthur, MD, UT Southwestern Medical Center

0:25

Sac-TMT Plus Pembrolizumab in TNBC

9 months ago

Heather McArthur, MD, MPH

Eric K. Singhi, MD, of MD Anderson Cancer Center

0:43

Recapping the IASLC 2025 World Conference on Lung Cancer

9 months ago

Eric K. Singhi, MD

0:34

How AI Is Reshaping Cancer Care

9 months ago

Mack Roach III, MD

1:00

DNA- and RNA-Based Sequencing in Lung Cancer

9 months ago

Joel Neal, MD, PhD

2:08

CISH Knockout TIL Therapy Using CRISPR Editing to Enhance T-Cell Function in GI Cancers

9 months ago

Beau Webber, PhD

1:04

The Evolving Treatment Paradigm for Leukemia and Lymphoma

9 months ago

Jorge Cortes, MD

0:45

The Importance of Early Recognition for Optimal Uterine Cancer Management

9 months ago

John Paul Diaz, MD

Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institue

0:44

Rationale for Combining Sac-TMT With Pembrolizumab in HR+, HER2– Breast Cancer

9 months ago

Sara M. Tolaney, MD, MPH

0:41

The Importance of a Consensus Manuscript to Bridge Gaps in Lung Cancer

9 months ago

Narjust Florez, MD

Paul Gellhaus, MD, discusses the importance of accurate diagnosis and effective management strategies to kick off Prostate Cancer Awareness Month

0:38

Common Disease, Critical Choices: Navigating Prostate Cancer Management

9 months ago

Paul Gellhaus, MD

0:34

Challenges in Transitioning to Research for Hematology/Oncology Fellows

9 months ago

Christine Ann Garcia, MD, MPH

0:40

Advice for Hematology/Oncology Fellows for Handling a New Cancer Diagnosis

9 months ago

Ashish Saxena, MD, PhD

Fawzi F Abu Rous, MD, discusses the investigation of the PD-L1 and VEGF-targeted bispecific antibody ivonescimab in NSCLC.

0:34

Ongoing Development of Ivonescimab in NSCLC

9 months ago

Fawzi F Abu Rous, MD

0:59

Minimally Invasive Surgery Should Be Carefully Explained to Patients With Lung Cancer

9 months ago

Geoffrey B. Pelz, MD

$Nisha Joseph, MD, and Hans Lee, MD, discuss the clinical significance of the FDA's approval of linvoseltamab for relapsed/refractory multiple myeloma.$

1:24

FDA Approval of Linvoseltamab for Relapsed/Refractory Multiple Myeloma

9 months ago

Nisha Joseph, MD(+1 more)

Connie Lai, MD, discusses a retrospective analysis comparing the use of post-induction treatment strategies for patients with metastatic colorectal cancer.

1:07

Retrospective Analysis of Post-Induction Treatment Strategies in mCRC

9 months ago

Connie Lai, MD

Video Shorts

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates